The Evolving Landscape of IPF Drug Discovery and Development
Idiopathic Pulmonary Fibrosis (IPF) remains one of the most challenging respiratory diseases to treat, characterized by progressive lung scarring and severely unpredictable disease progression. Despite high unmet clinical needs, the current standard of care—antifibrotic therapies nintedanib and pirfenidone—offers only modest benefits, with ongoing side effects that are a significant burden to patients. In our latest […]
TherapeutAix to attend ERS Congress 2024
TherapeutAix will be at the ERS Congress 2024 taking place in Vienna, Austria from 7-11th September. The Congress, hosted at RX Messe Wien, will bring together the world’s respiratory experts to showcase the latest advances in respiratory medicine and science. The theme of this year’s Congress is ‘Humans and machines: getting the balance right’ and focus […]
Fraunhofer 2024 Meeting
In late June, Simon Cruwys (Director, Pharmacology) attended and presented at the Fraunhofer Models of Lung Disease 2024 meeting in Hannover. This conference brought together speakers and experts from industry and academia to discuss the latest advances respiratory research. This year’s meeting focused on infection, clinical development, epidemiology, prevention and drug development in respiratory diseases. […]
ECM2024 meeting
In late June, Darcey Black (Director, Translational) attended and presented at the ECM2024 meeting in Copenhagen. This conference brought together speakers and experts from industry and academia to discuss the latest advances in fibrosis and related research. ECM2024 covered a range of topics around the theme of the “ExtraCellular Matrix” (hence the title!), and […]
Updates from SMR Meeting: ‘The Innovation Landscape’
Back in July 2022 the SMR (Society for Medicines Research) hosted a conference on ‘Innovative new pharma and biotech partnerships: How is the landscape transforming?’ That conference looked at ongoing developments in pharmaceutical discovery and development, focused on the need for partnerships between large pharmaceutical and new biotech companies to tackle the next generation therapeutic […]
First drug approval in NASH
When we reviewed the R&D landscape in nonalcoholic steatohepatitis (NASH) in 2018, we highlighted 4 development programs that were in Phase 3 development and all targeting pivotal data readout, and a potential launch, between 2019 and 2021. However, obeticholic acid, elafibranor, cenicriviroc, and selonsertib all turned out to not confirm their initial positive data in […]
SMR meeting: The Innovation Landscape
On Tuesday 26 March Darcey Black, Translational Science Director at TherapeutAix, will be co-organising and co-sharing the SMR meeting taking place at Friends House, London. This SMR meeting follows on from the 2022 conference on ‘Innovative new pharma and biotech partnerships: How is the landscape transforming?’ and its goal is to better understand these evolutionary […]
Welcome 2024
With the New Year up and running, we all got together in Aachen for a Board Meeting. In addition to mapping out activities for 2024, we focused on two additional areas. The first was a strategic review of our services and how these align with our client’s needs. While we’re receiving superb feedback in our […]
TherapeutAix Roundup: 2023
As 2023 comes to an end we wanted to take the time to reflect upon the year and share what we have been up to. From supporting our clients, participating in scientific meetings, and facilitating workshops to refreshing our website, it has been a busy year for the team at TherapeutAix. Our clients and their […]
SMR: Recent Clinical Candidates and SMR Award Meeting
Darcey Black, Translational Science Director at TherapeutAix, will be attending the bi-annual SMR Meeting taking place at Friends House, London, on Monday 4th December. The meeting will include presentations highlighting recent clinical candidates across therapeutic areas including cancer, immune disease and more, with a variety of targeting modalities. The meeting will include the presentation of […]